Effectivity of Dexamethasone Fighting Cytokine Storm in Severe COVID-19 Patients; Does it still reliable used for COVID-19?

Authors

  • Syahrul Tuba The Republic of Indonesia Defense University
  • Muhammad Rifly Aprianto The Republic of Indonesia Defense University

DOI:

https://doi.org/10.55927/fjst.v1i3.835

Keywords:

SARS-Cov-2, Corticosteroid, Dexamethasone, Covid-19

Abstract

Covid-19 has been declared a pandemic by WHO (World Health Organization) since March 2020. However, there is confusion about the therapy that should be used for covid-19. This virus enters the human body by binding to ACE-II receptors in the human body, causing an inflammatory response and a decrease in the body's immune response. The overproduction of pro-inflammatory cytokines relates to COVID-19's cytokine storm, also known as cytokine release syndrome (CRS). The aim of this article is to determine the effectiveness of dexamethasone in treating cytokine storms in severe COVID-19 patients using ventilator respiratory. This study used a narrative review journal from several leading platforms such as PubMed, NEJM, NCBI, and others, as well as from government websites, selected between 2019 and 2021 in the English language. Dexamethasone is a corticosteroid class of drugs that can act as anti-inflammatory and immunosuppressive. The drug inhibits the expression of genes that induce inflammatory proteins. In the case of severity covid-19, dexamethasone was used in patients who had decreased oxygen saturation. After being treated using this drug intravenously, the patient showed a positive increase in oxygen saturation levels. Dexamethasone therapy was effective and may have been acceptable in severe Covid-19 patients that actively ventilator respiratory. Then, a more rigorous investigation of the impact of dexamethasone is needed.

Downloads

Download data is not yet available.

References

W. G. dos Santos, "Natural history of COVID-19 and current knowledge on treatment therapeutic options," Biomed. Pharmacother., vol. 129, p. 110493, Sep. 2020, doi: 10.1016/J.BIOPHA.2020.110493.

B. Pamukçu, "Inflammation and thrombosis in patients with COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2," Anatol. J. Cardiol., vol. 24, no. 4, pp. 224–234, Oct. 2020, doi: 10.14744/ANATOLJCARDIOL.2020.56727.

“Coronavirus disease (COVID-19): Dexamethasone.” https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-dexamethasone (accessed Jul. 29, 2021).

"Dexamethasone briefing - its chemistry and history - The Cambridge Crystallographic Data Centre (CCDC)." https://www.ccdc.cam.ac.uk/Community/blog/dexamethasone/ (accessed July 29, 2021).

S. Ramamoorthy and J. A. Cidlowski, "Corticosteroids-Mechanisms of Action in Health and Disease," Rheum. Dis. Clin. North Am., vol. 42, no. 1, p. 15, 2016, doi: 10.1016/J.RDC.2015.08.002.

K. AG et al., "Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial," Trials, vol. 19, no. 1, Dec. 2018, doi: 10.1186/S13063-018-3050-4.

R. J. Flower and F. Gavins, "Dexamethasone," xPharm Compr. Pharmacol. Ref., pp. 1–6, Jan. 2008, doi: 10.1016/B978-008055232-3.61572-7.

M. H. Ahmed and A. Hassan, "Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review," SN Compr. Clin. Med. 2020 212, vol. 2, no. 12, pp. 2637–2646, Oct. 2020, doi: 10.1007/S42399-020-00610-8.

K. Sharun, R. Tiwari, J. Dhama, and K. Dhama, "Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence," Int. J. Surg., vol. 82, p. 179, Oct. 2020, doi: 10.1016/J.IJSU.2020.08.038.

R. HA and B. SN, "The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak," J. Autoimmun., vol. 109, May 2020, doi: 10.1016/J.JAUT.2020.102433.

World Health Organization, "COVID-19 Weekly Epidemiological Update," World Heal. Organ., no. December, pp. 1–3, 2021, [Online]. Available: https://www.who.int/docs/default-source/coronaviruse/situation-reports/weekly_epidemiological_update_22.pdf.

D. M. Williams, "Clinical Pharmacology of Corticosteroids," Respir. Care, vol. 63, no. 6, pp. 655 LP – 670, Jun. 2018, doi: 10.4187/respcare.06314.

W. Y, S. J, G. R, B. RS, and L. F, "Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus," J. Virol., vol. 94, no. 7, Mar. 2020, doi: 10.1128/JVI.00127-20.

M. C. Chappell, A. C. Marshall, E. M. Alzayadneh, H. A. Shaltout, and D. I. Diz, "Update on the Angiotensin Converting Enzyme 2-Angiotensin (1–7)-Mas Receptor Axis: Fetal Programing, Sex Differences, and Intracellular Pathways," Front. Endocrinol. (Lausanne)., vol. 4, no. JAN, 2013, doi: 10.3389/FENDO.2013.00201.

H. T et al., "ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation," Nature, vol. 487, no. 7408, pp. 477–481, Jul. 2012, doi: 10.1038/NATURE11228.

D. Y et al., "Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways," J. Pathol., vol. 203, no. 2, pp. 622–630, Jun. 2004, doi: 10.1002/PATH.1560.

D. C. Fajgenbaum and C. H. June, "Cytokine Storm," https://doi.org/10.1056/NEJMra2026131, vol. 383, no. 23, pp. 2255–2273, Dec. 2020, doi: 10.1056/NEJMRA2026131.

M. Soy, G. Keser, P. Atagündüz, F. Tabak, I. Atagündüz, and S. Kayhan, "Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment," Clin. Rheumatol., vol. 39, no. 7, p. 1, Jul. 2020, doi: 10.1007/S10067-020-05190-5.

"Clinical Spectrum | COVID-19 Treatment Guidelines." https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ (accessed July 29, 2021).

"Certain Medical Conditions and Risk for Severe COVID-19 Illness | CDC." https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (accessed July 29, 2021).

Y. Zhang, S. Hu, J. Wang, Z. Xue, C. Wang, and N. Wang, "Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2," Virology, vol. 554, p. 83, Feb. 2021, doi: 10.1016/J.VIROL.2020.12.001.

M. Amin Langarizadeh, M. R. Tavakoli, A. Abiri, A. Ghasempour, M. Rezaei, and A. Ameri, "A REVIEW ON FUNCTION AND SIDE EFFECTS OF SYSTEMIC CORTICOSTEROIDS USED IN HIGH-GRADE COVID-19 TO PREVENT CYTOKINE STORMS," EXCLI J., vol. 20, pp. 339–365, 2021, doi: 10.17179/excli2020-3196.

A. A. Rabaan et al., "Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm," Vaccines, vol. 9, no. 5, May 2021, doi: 10.3390/VACCINES9050436.

C. L et al., "[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]," Zhonghua Jie He He Hu Xi Za Zhi, vol. 43, no. 3, pp. 203–208, Mar. 2020, doi: 10.3760/CMA.J.ISSN.1001-0939.2020.03.013.

H. ME, H. HM, S. K, E. A, and E. MM, "Dexamethasone in severe COVID-19 infection: A case series.," Respir. Med. Case Reports, vol. 31, pp. 101205–101205, Aug. 2020, doi: 10.1016/J.RMCR.2020.101205.

Downloads

Published

2022-07-31

Issue

Section

Articles